What if the neuropathy in front of you isn’t what it seems? Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immune-mediated peripheral neuropathy, yet it remains widely underrecognized. Because its symptoms mimic other neuropathies, CIDP is too often misdiagnosed …
Lupus nephritis (LN) is one of the most consequential organ manifestations of systemic lupus erythematosus (SLE), occurring in approximately 40% to 60% of patients, most often within the first 5 years of diagnosis, and progressing to end-stage kidney disease in …
Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …
Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …
Extraintestinal manifestations (EIMs) affect up to one-third of patients with inflammatory bowel disease (IBD) and can significantly contribute to morbidity, impaired quality of life, and long-term disease burden, yet they remain inconsistently recognized and managed in clinical practice. Many gastroenterologists …
Although treatment advances in inflammatory bowel disease (IBD) have improved symptom control, many patients continue to experience progressive structural bowel damage and systemic complications that are not adequately addressed in routine care. Gastroenterologists and multidisciplinary gastrointestinal (GI) care teams often …
Systemic health inequities disproportionately impact underserved racial and ethnic populations, leading to higher morbidity, mortality, and reduced quality of life. Socioeconomic disadvantages, racial bias, and barriers to care contribute to these disparities, yet they often go unnoticed by health care …
The rapidly evolving multiple myeloma (MM) treatment landscape has created unprecedented opportunities, while introducing new complexities for clinicians caring for patients with relapsed/refractory (R/R) disease. In just a few years, bispecific antibodies (BsAbs) have emerged as highly effective treatment options, …
It is increasingly understood that multiple sclerosis (MS) relapse and progression can occur simultaneously, regardless of phenotype, revealing flaws in the traditional classification of MS and prompting increasing use of a spectrum-based view of the disease. This shift is reflected …